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Abstract.  The adaptation of the serpin framework and its mechanism to perform diverse functions 
is epitomised in the hormone carriers of the blood. Thyroxine and the corticosteroids are transported 
bound in a 1:1 ratio on almost identical sites in the two homologous binding-globulins, TBG and 
CBG. Recent structural findings show an equilibrated, rather than on-and-off, release of the 
hormones from the carriers, reflecting small reversible movements of the hinge region of the 
reactive loop that modify the conformational flexibility of the underlying hormone-binding site. 
Consequently, contrary to previous concepts, the binding affinities of TBG and CBG are not fixed 
but can be allosterically modified to allow differential hormone delivery. Notably, the two carriers 
function like protein thermocouples with a surge in hormone release as body temperatures rise in 
fevers, and conversely a large diminution in free hormone levels at hibernation temperatures. By 
comparison angiotensinogen, the source of the angiotensin peptides that control blood pressure, 
does not appear to utilise the serpin mechanism. It has instead evolved a 63 residue terminal 
extension containing the buried angiotensin cleavage site, which on interaction moves into the 
active cleft of the renin. The conformational shift involved is critically linked by a labile disulphide 
bridge. The observation of changes in the redox status of this S-S bridge, in the hypertensive 
complication of pregnancy, pre-eclampsia, has opened an unexpected level of regulation at what is 















The realisation that members of the serpin family all share the same conserved template structure    
[1] brought with it challenges. A first was how had this single template been adapted to provide 
such a diversity of functions? But the more puzzling question was why the serpins had been 
preferentially selected as controlling factors in the critical pathways of higher organisms, including 
coagulation, fibrinolysis and tissue development and growth? Answers ultimately followed from the 
structural demonstration of the conformational transition of the serpins that results in the essentially 
irreversible inactivation of their target proteases [2]. The ability of the serpins to undergo this 
remarkable change of fold (Fig 1a) had been indicated much earlier in the first of the serpin 
structures, that of reactive-loop cleaved α1-antitrypsin and then that of an intact serpin, ovalbumin 
[3,4].  The demonstration of the generality of this S-to-R conformational transition from a stressed 
to a relaxed form in cleaved serpins [5] led to the prediction of its likely adaptation in the intact 
serpin to allow the modulation of activity [6,7] - a prediction now satisfyingly confirmed in 
structural detail with the human plasma hormone carriers. 
 
2. Serpins and the concept of molecular mobility 
 
It needs to be recalled that the concept of molecular mobility, the ability of proteins to readily 
undergo major changes in conformation, arose from the early studies of the serpins. It was a 
controversial concept. At the time of crystallisation of ovalbumin in 1989 there were relatively few 
solved protein structures and the accepted view amongst crystallographers was that the folds of the 
known structures were firmly defined, subject to only minor localised changes in conformation.  
The structure of cleaved α1-antitrypsin led to a necessary, albeit reluctant, acceptance by the field 
that cleavage of the reactive loop in serpins could induce a radical conformational transition. This 
was reinforced by the finding of a spontaneous loss of activity in another serpin, PAI-1, due to the 
irreversible S-to-R incorporation of its intact, uncleaved, reactive loop [8]. Nevertheless, the 
proposal of the occurrence of a constantly dynamic and fluctuating movement of the reactive loop, 
as in Fig 1b, was met with scepticism and even, by some, with opposition. There was for years a 
reluctance to accept that reversible modulatory transitions, as we can now see with the hormone-
binding globulins, could occur in the intact serpin. This reluctance had a practical downside as it led 
to the consideration of serpin function solely in terms of the full S-to-R transition; in terms of 
simple on-and-off mechanisms or, for the hormone-carrying globulins, a defined transition from a 
binding to a non-binding state. The revelation that the release of hormones from their serpin 
transporters in the blood is not an on-and-off process but is subtly modulated by dynamic 
movements of the intact reactive loop, is now opening new understandings in endocrine medicine 
[9,10]. 
 
3. Recognition of the hormone carriers 
 
Initially the recognition and naming of the serpins as a protein family focused on the protease 
inhibitors in human plasma [11-16]. But at the same time there was also much interest in the 
identification in human plasma of three non-inhibitory members of the serpin family – the hormone 
carriers: angiotensinogen [17], thyroxine-binding globulin [18] and corticosteroid-binding globulin 
[19]. The alignment of the sequences of the three hormone-carriers with other serpins provided 
immediate clues as to their function. The presence of atypical reactive-centre sequences made it 
unlikely that these newly identified serpins retained any inhibitory function and this was further 
excluded with angiotensinogen [20] by a reactive loop hinge sequence (P15-P12) that was 
incompatible with ready loop-insertion into the A-sheet. TBG and CBG however, having lost any 
inhibitory activity, do retain the characteristic hinge-sequence of an active serpin. Both were shown 
to undergo the typical S-to-R serpin transition [21], with proteolytic cleavage of their reactive 
loops, as in sites of inflammation, resulting in hormone release [21-24].  
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The good sense that this mechanism makes was in a way misleading, as it reinforced the concept 
that the carriage of thyroxine and corticosteroids is an on-and-off event, with the release from their 
carriers being triggered by the S-to-R irreversible transition. A hint, however, of a more subtle 
hormone release mechanism came with the observation by Stein [21] that cleavage of CBG resulted 
in a partial rather than complete release of the bound cortisol. Although TBG and CBG received 
much attention in the 1980s, further understandings had to await their crystallisation, which, as with 
angiotensinogen, proved to be refractory until the new millenium. 
 
4. Serpins and allosteric modulation 
 
In the meantime, the wider modulatory potential of the serpin conformational mechanism had 
become evident, notably with the loop-changes associated with the activation of antithrombin by 
the heparin pentasaccharide Whereas in the prior structures of antithrombin in the absence of 
heparin [25] the reactive loop was seen to be partially inserted, a later structure showed that on 
complexing with heparin an extension of the D-helix took place with an accompanying full 
expulsion and hence activation of the reactive loop  [26].  It was at first assumed that this allosteric 
activation of antithrombin functioned as an on-off switch but a subsequent structure of the heparin-
antithrombin complex surprisingly showed, contrary to the previous structure of the same complex, 
a partial incorporation of the reactive-loop into the central β-sheet A [27]. The demonstration of 
these two alternative conformations in the same complex provides direct structural evidence that the 
intact reactive-loop can move dynamically into and out of the A-sheet, with the binding of heparin 
resulting in a shift of the equilibrated balance in favour of full exposure of the loop. In this way 
antithrombin provides a paradigm for the allosteric regulation of serpin activity. It is this in-built 
potential of the serpins to allow a responsive modulation of activity that explains their selection and 
adaptation as the controlling factors in key metabolic and intracellular processes, as notably seen 
with the hormone carrying globulins, TBG and CBG.  
 
5. Thyroxine and cortisol 
 
5.1 Thyroxine is the main hormone controlling our activity, with its immediate derivatives 
regulating cellular oxygen consumption and the metabolism of body and brain. It is a small 
molecule formed by the linkage of two tyrosines, which are iodinated to give alternative tri- or 
tetra-iodo forms of the hormone [28]. The steady-state concentration of free thyroxine in the blood 
is ultimately set centrally by the secretion of the thyroid stimulating hormone TSH, but the 
maintenance of the concentration of the free hormone, at near 20pM throughout the tissues, results 
from the equilibrated release of thyroxine from TBG. The binding affinity of TBG for thyroxine is 
exceptionally tight (Kd ~80pM) with TBG acting as a circulating store of the hormone and only 
0.03% of the total thyroxine being in the free form in blood [29]. The binding capacity of 
circulating TBG is only partially saturated, and it is the percentage saturation of TBG, of 20% or 
more, that by the law of mass action determines the concentration of free thyroxine in the blood. 
This then, till recently, has been the accepted role of both TBG and CBG, as simple carriers that 
give an equilibrated release to maintain uniform free concentrations of their hormone throughout 
the tissues.  This relationship between the percentage saturation of the binding transport proteins, 
TBG and CBG, and the free-hormone concentration, is based however on the assumption that the 
hormone-binding affinity remains a constant throughout. A singular achievement of the structural 
advances of the last decade has been to overturn this assumption and to reveal an allosteric 
mechanism in both TBG and CBG that adjusts the affinity of binding to give a responsive release of 





5.2 Cortisol is a steroid hormone critical for the maintenance of life and for survival in stress, 
which acts by increasing glucose production and suppressing the immune response. Cortisol is 
transported in a 1:1 ratio by CBG, which serves as a circulating store binding nearly 90% of the 
total in the blood. Critically it is the equilibrated release of cortisol from CBG that buffers and 
regulates the plasma concentration of free cortisol, as analogously so with thyroxine and TBG. The 
affinity of binding of cortisol by CBG however is much less than that of thyroxine by TBG, with 
the Kd of CBG being in the nanomolar range versus the picomolar range of TBG. Also, whereas 
TBG circulates in a partially saturated state, the release of cortisol from the adrenal cortex can 
exceed the binding capacity of CBG resulting in its complete saturation and hence 
disproportionately high levels of free cortisol [34,35]. For the most part though, a steady state 
concentration of cortisol throughout the tissues is maintained with the binding capacity of CBG 
being only partially saturated. For example in a healthy adult a typical free cortisol concentration of 
13nM [36] will result from a 29% saturation of CBG. This then, as with TBG and thyroxine, has 
been the accepted role of CBG as a simple carrier that gives an equilibrated release of the hormone 
to maintain uniform free cortisol concentrations throughout the tissues. The assumption, as had 
been so with TBG, was that the hormone-binding affinity of CBG remained a constant throughout.  
 
 
6. TBG and CBG 
 
TBG and CBG are both glycoproteins that retain the typical template serpin structure but with 
notable differences from the consensus in the sequences of their reactive centre loops. The unique 
presence in the TBG of all species of a proline at P8 (8-residues prior to the reactive centre - fig 1b) 
indicates a purposeful impedance to full loop insertion, and the conservation of a proline at P1’ is in 
keeping with TBG's non-inhibitory status. A feature of the reactive loop in CBG, as opposed to 
TBG and the serpin consensus, is the presence of a valine rather than the polar threonine at the P14 
hinge of the reactive loop. The entry of the P14 side-chain into the A-sheet is now believed to 
trigger the allosteric mechanism (fig 2), the presence of the bulky non-polar valine being in keeping 
with the more ready and greater magnitude of the allosteric response in CBG versus TBG. 
 
6.1 Structures and the allosteric mechanism of hormone release.  The allosteric mechanism and 
its modulatory potential has recently become evident with the solving of a series of structures of 
TBG and CBG [30-33, 37]. The two binding globulins have closely similar structures, with 
thyroxine and cortisol each binding to near identical pockets on the serpin framework, between 
helices H and A and strands 3-5 of the B-sheet (Figs 1a, 2). Each hormone forms a series of 
hydrophobic and polar bonds with the residues lining the pockets. In TBG the binding of thyroxine 
is stabilised by a cation-π interaction with the positively-charged guanidinium of an arginine, 
whereas in CBG the main interaction is a π-π stacking between a homologous tryptophan and the 
cycloalkene rings of cortisol.  
Although the first crystal structures of the TBG and CBG hormone-complexes were interpreted in 
terms of a tight specificity of binding, subsequent structures emphasise the plasticity of the pockets, 
with the interactions of the liganded hormones within the pocket being reflected in the affinity 
rather than precise specificity of binding. Thus both globulins can still bind their respective 
hormones even after cleavage and transition to the R-form, although with a substantially reduced 
affinity [9]. Likewise other structures show that the TBG pocket can readily accommodate a range 
of thyroxine analogues and unrelated drugs and dyes, though again with a lesser affinity [33]. 
Remarkably, but perhaps not surprisingly, the substitution of the key tryptophan in the binding 
pocket of CBG by the homologous arginine of TBG changes the binding specificity of CBG from 
cortisol to thyroxine: in effect the engineered CBG becomes a TBG [38]. 
 
Earlier evidence that movements of the reactive loop influenced the ligand affinity of the binding-
globulins came from the demonstration that a shortening of the reactive loop of TBG resulted in an 
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increased affinity for thyroxine and conversely a lengthening of the loop gave a decreased affinity 
[39]. The explanation for this became apparent with the solving of the structure of the TBG-
thyroxine complex [30].  This, with ancillary evidence from natural variants of TBG [40] indicated 
the existence of a flip-flop modulatory mechanism, with the affinity of the binding of thyroxine 
being governed by a limited movement (P14-P8) of the reactive-loop into and out of the A-sheet, as 
demonstrably occurs with antithrombin. Similarly, TBG crystallised as does active antithrombin, 
with its reactive-loop partially incorporated in the A-sheet, to the level of a conserved threonine at 
P14 (Figs 1b, 2). The complete insertion of the sidechain of the P14 threonine is impeded by a 
similarly conserved underlying tyrosine residue, Tyr 241 in the s2B/3B loop, which critically 
interacts with underlying peptide loops of the B-sheet that bind to and flank thyroxine in the 
binding pocket (Fig 2b,c). 
 
Although the displacements resulting from the complete insertion of the side-chain of the P14 Thr 
can trigger further hormone release, we now believe that the fine-tuning of the physiological 
balance between the bound and unbound hormones principally occurs with the initial entry of the 
loop into the A-sheet. This is better described, perhaps, as a nudge-nudge rather than flip-flop 
movement. The significance of this small initial movement of the loop into and out of the sheet, at 
the level of P14, became apparent with the determination of the structure of CBG [28]. This 
showed, as compared to the TBG structure, a fully exposed reactive loop and an accompanying 
unwinding of the D helix, with the two structures, of TBG and CBG, providing a strikingly 
comparable identity with the antithrombin heparin-bound and unbound structures, respectively.  
Subsequent structural studies have confirmed the role of this limited movement of the loop, in TBG 
as well as CBG, in modifying the affinity of hormone binding. Entry of the reactive-loop will result 
in an expansion of sheet A with a consequent reordering of the loop that connects strand 2 of the A-
sheet with the top of the D helix. This connecting loop is in turn in close contact with loop s2/3B 
and it in turn with loop s4B/5B that flanks the binding pocket. As in Fig 2b, any slight changes in 
the packing of these loops will affect the plasticity of the pocket and perturb the polar and 
hydrophobic bonds that anchor the hormone in the binding site. 
 
Thus contrary to earlier concepts of a simple on-off mechanism, it is now evident that the binding 
and release of hormones from the carrier-globulins is a much more subtle process, primarily 
reflecting an allosteric and dynamic equilibrium in both CBG and TBG between high and low 
affinity conformers of the intact circulating proteins. Inherent to this, the uptake and release of the 
hormones will be dependent on tissue concentrations of the unbound hormones, with the carrier 
proteins acting as buffers to evenly maintain the optimal concentrations of the free hormones. 
 
 7. Hormone-binding globulins: physiological and medical implications. 
 
The revelations, from recent structural advances, of an allosteric release mechanism in both TBG 
and CBG have direct medical and physiological implications [10]. 
 
7.1 Inflammation and cleavage. The finding that the cleavage of TBG and CBG by neutrophil 
proteases resulted in a loss of binding-affinity initially focused attention on the release of hormones 
at foci of inflammation. But a realisation of the wider significance of this proteolytic transition has 
become apparent from a study that defined the range of changes in binding-affinity, Kd, that can 
take place in plasma CBG [9]. Cleavage of the reactive loop in CBG results in a large diminution 
but not a loss of binding affinity. There is a tenfold increase in Kd from 32nM to 292nM, which 
will result in the release of most of the bound cortisol but by no means all, with the retention by the 
cleaved CBG of a binding saturation near 4%. In a compartmented area where blood flow is 
sluggish, as in an indurated site of inflammation, a total cleavage of CBG would result in a 4-fold 
spike in free cortisol, accompanied by a re-equilibration within the compartment of the percentage 
saturation of the cleaved CBG to 16%, a level at which it could effectively buffer the raised free 
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cortisol level. The concept that the cleaved and apparently inactivated CBG might have a role 
systemically, as a backup buffer to that of the intact circulating intact CBG, has become a 
likelihood with the recent development of an immunoassay capable of differentiating the two forms 
of CBG (41,42).  The half-life of cleaved CBG in the plasma has now been shown to be the same as 
that of intact CBG, with in severe sepsis the rise in plasma levels of the cleaved form reaching near 
equivalence to that of the intact form [43,44]. Thus, the structurally-derived finding, that the 
cleaved hormone carriers retain a significant binding-affinity, has led to the realisation that in 
severe systemic inflammation there will be two major buffering systems: that of the intact carrier 
with a high hormone affinity and that of the cleaved carrier with a manifold lower affinity.  
 
7.2 A Protein Thermocouple. Individual proteins have evolved to function optimally at the kinetic 
flexibility present at 37oC. This is particularly true of the interactions of proteins with ligands, and it 
was predictable that the hormone-binding affinity of TBG and CBG would decrease with rises in 
body temperature [45]. Earlier findings with another serpin, antithrombin, had highlighted a special 
additional factor, in the temperature dependence of its modulatory mechanism. As with TBG and 
CBG, the mechanism that controls the activity of antithrombin involves small 'nudge-nudge' 
movements of the reactive centre loop into and out of the body of the molecule. The sensitivity of 
these movements to changes in temperature became apparent in patients with mutations in their 
antithrombin that marginally facilitated the entry of the reactive loop [46]. The affected individuals 
remain fit and well unless they develop a fever. Then even a small increase in their body 
temperature, as can occur with a minor infection, is sufficient to increase reactive loop mobility 
with, in the special case of these mutants, a consequent inactivation of the mutant antithrombin and 
the consequent onset of thrombosis. Thus an immediate deduction that arose with the solving of the 
structure of TBG was that its loop-responsive hormone release mechanism would be similarly 
temperature responsive [30]. As shown in Fig 3, TBG effectively functions as a protein 
thermocouple: as body temperature decreases and the basal metabolic rate declines, there will be an 
accompanying increase in binding affinity and an appropriately decreased release of thyroxine. 
Conversely, when the temperature rises above 37oC, as in fevers, there will be a boosted release of 
thyroxine, with the equilibrated concentration of free thyroxine at 39 oC predictably increasing to 
near thyrotoxic levels.  
 
Evidence that this potential boost of thyroxine release in fevers is purposeful comes from the 
presence in an Australian aboriginal population of an adaptive mutation, a replacement of alanine 
191 by a threonine, that turns off the temperature-induced acceleration of thyroxine release [29]. 
Alanine 191 (Fig 2b) is immediately adjacent to the point of entry of the reactive loop into the A-
sheet of TBG, and its replacement by a polar threonine will predictably affect the H-bond network 
that links to the bound thyroxine. The replacement critically results (Fig 3b) in an abolition of the 
accelerated release of thyroxine that otherwise takes place as the temperature rises above 37ºC. 
Whereas a fever body-temperature of 39oC will predictably cause an increase in free thyroxine 
concentrations to what in health would be thyrotoxic levels, the mutation in the aboriginal TBG 
limits this increase to within the normal euthyroid range [29].  Deductively, this diminished rise in 
free thyroxine will be of survival advantage, especially so in infancy, in providing a reduced 
metabolic response to increased body temperatures in fevers, in an arid environment where ambient 
temperatures can rise above 45 degrees centigrade. 
 
The effect of changes in temperature on the much more sensitive release mechanism of CBG is 
even more striking (Fig 3a). Whereas with TBG there will be a 25% increase in free thyroxine as 
body temperature rises above 39oC, with CBG there will be a threefold or more increase in free 
cortisol [9,10,47]. These are changes that rapidly re-equilibrate as the temperature rises and falls. A 
patient in fever may have a threefold increase in free cortisol but this will revert almost immediately 
to a normal level as the body is cooled to 37oC. Similarly, and confusingly so, if a blood sample 
taken during a fever is then analysed in the laboratory at 37oC, the result represents what the free 
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cortisol concentration is in the blood sample at 37oC and not what it was in vivo at the time of 
sampling. Disconcertingly, measurements of the free hormone determined at room temperature, as 
often done, are only of direct relevance if the patient is dead! 
 
7.3 Fevers and hot baths. The recently revealed temperature sensitivity of hormone release from 
TBG and CBG has profound implications in physiology and medicine [10,29,47]. The decrease in 
thyroxine release with decreases in body temperature will play a central part in the cyclical 
hypothermia and dormancy of small mammals. The changes in humans, though more subtle, will 
still affect our everyday lives. The reversible changes in binding affinity will occur locally to 
extremities as well as systemically to the whole body. Conversely the burst of thyroxine and 
cortisol release with the rise in body core temperature to 39ºC in a hot bath or sauna explains the 
accompanying feeling of well-being and mental stimulus – the euphoria and eureka! The new 
understandings give a glimpse of how bodily processes move into overdrive in fevers. A rise of just 
one or two degrees C will automatically raise the blood free thyroxine to a concentration that in 
health would move into the hyperthyroid range. With corticosteroids the same increase in 
temperature will lead to a massive release from the circulating store in CBG, to give a two or 
threefold increase in plasma free cortisol. Fever is clearly a universal defensive response to 
infection and inflammation, and it is not difficult to see how such increases in active thyroxine and 
cortisol will be of benefit to the body in a crisis.  
7.4 Conclusions: CBG & TBG  
The findings with CBG and TBG highlight the reasons for the selection of serpins as the controlling 
factors in the critical pathways of higher organisms. The inherent ability to modify the functional 
activity of serpins, by influencing the dynamic movements of their reactive loop, provides a means 
of adjusting activity to meet the differing requirements of individual tissues and organs. Examples 
of this responsive modulation are apparent in fevers and inflammation, and the challenge ahead is to 
identify the receptors and ligands [48] that will predictably influence the conformational flexibility 
and hormone affinity of CBG and TBG in specific tissues. 
8. Angiotensinogen 
 
Angiotensinogen plays a pivotal role in physiology, by serving as the substrate in the first and rate-
limiting step of the renin-angiotensin system (RAS) that controls blood pressure by influencing salt 
retention and vasoconstriction [49,50].  The pathway is initiated by the highly specific release of the 
decapeptide angiotensin-1 from the N-terminus of angiotensinogen by the enzyme renin.  Although 
angiotensinogen is secreted from the liver and is present in the plasma in relatively high 
concentration (0.8 μM), it is now believed that its primary action occurs at a tissue and cellular 
level, with the efficiency of cleavage being greatly increased by the interaction of renin with the 
membrane (pro)renin receptor or (P)RR [51]. Angiotensinogen has typically been regarded as the 
passive carrier of angiotensin-1, often illustrated with a figure showing the N-terminal peptide 
emerging from a featureless blob.  In light of the understanding that the hormone-binding globulins 
exploit the whole conformational repertoire of the inhibitory serpins to exercise subtle control of 
hormone levels, it was reasonable to expect that similar considerations had led to the evolutionary 
choice of the serpin framework for angiotensinogen as well.  Unlike the hormone-binding globulins, 
however, angiotensinogen was not expected to undergo the sheet expansion found in inhibitory 
serpins [20].  Though it has emerged from structural and biochemical studies that angiotensinogen 
indeed is also not a passive carrier, the mechanism by which it appears to play an active role in 
modulating blood pressure came as a surprise. 
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8.1 The crystallographic determination of the structure of angiotensinogen, which triggered 
these new insights, was the culmination of 20 years of work, in which the initial crystals of human 
AGT diffracted too poorly and the structure determination was hampered by the lack of known 
structures of serpins sharing more than about 20% sequence identity.  In the end, it was solved by 
the simultaneous use of X-ray data from crystals of human, rat and mouse angiotensinogen, in 
which the electron density could be improved iteratively by averaging images from different 
crystals [52].  This process yielded first the structure of rat angiotensinogen, which could be used to 
solve a structure of mouse angiotensinogen at a resolution of 2.2 Å, which in turn finally allowed 
the structure of human angiotensinogen to be determined at 3.3 Å resolution.  The 63-residue N-
terminal extension containing the angiotensin peptide forms an ordered superstructure wrapped 
around the serpin body, bound by two new helices (Fig 4a).  Surprisingly, the cleavage site was 
seen to be buried, packed against the body of the protein and inaccessible to renin. 
8.2. Interaction with renin. To understand how the cleavage site becomes exposed, crystals of a 
complex of human angiotensinogen with an inactive mutant of renin were grown.  The complex 
structure (Fig 4b) revealed that the cleavage site, between residues Leu10 and Val11 of 
angiotensinogen, moves by about 20 Å to enter the renin active site.  At the same time, the CD loop 
of angiotensinogen has to change conformation to avoid a clash with the surface of renin, and it was 
intriguing to see that these two conformational changes are coupled by a disulphide bridge between 
Cys18, near the cleavage site, and Cys138, in the CD loop.  
Previous work [53,54] had focused attention on this disulphide, which is conserved among different 
angiotensinogen sequences.  The structures, with their conformational changes, showed that it was 
well placed to play a role in the function of angiotensinogen, if its state could be varied.  Indeed, 
assays of serum samples from healthy volunteers showed that this disulphide exists as a mixture of 
40% reduced and 60% oxidized [50], unlike the majority of structural disulphides that are 
essentially completely oxidized.  The redox potential of this disulphide was measured as -230 mV 
[52], within the range of -184 to -255 mV found for known allosteric disulphides [53]. 
Changing the state of the Cys18-Cys238 disulphide, in turn, can affect the function of 
angiotensinogen as a substrate for renin.  In keeping with current understanding that the critical 
release of angiotensin takes place focally at a cellular level in renal and other tissues [56], the state 
of the disulphide only has a significant effect in the presence of the (pro)renin receptor; in this 
circumstance, the catalytic efficiency for release of angiotensin-1 by renin is four-fold greater for 
oxidized angiotensinogen than for reduced angiotensinogen [52].  Although this is a relatively small 
effect, it is similar in size to the effect of a Leu10Phe mutation of angiotensinogen associated with 
increased risk of pre-eclampsia, which causes a two-fold increase in catalytic efficiency [57].  
8.3 Oxidation and pre-eclampsia. The biochemical finding of increased catalytic efficiency 
correlated with the association found between oxidative stress and hypertension in general [58] or 
pre-eclampsia in particular [59,60].  To determine whether the increased oxidative stress of pre-
eclampsia leads, as predicted, to an increase in the proportion of oxidized angiotensinogen, blood 
samples from women suffering from pre-eclampsia were compared to those from matched 
normotensive controls at a similar stage of pregnancy.  This showed a statistically-significant 
increase in oxidized angiotensinogen [52, 61]. Together, these results suggest that the lability of the 
Cys18-Cys138 bridge provides an additional mechanism to modulate the control of blood pressure, 
and that this lability explains, at least in part, the connection between oxidative stress and pre-
eclampsia. 
8.4. Divergent evolution. Although this work showed that angiotensinogen is not, in fact, just a 
passive carrier of angiotensin-1 but rather plays a more active role through the influence of the 
labile disulphide on catalytic efficiency, it does not answer the question of why evolution chose the 
serpin framework for this role.  No evidence has emerged yet for any influence of the archetypal 
serpin conformational changes on the role of angiotensinogen in humans or other mammals.  
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However, it is intriguing to note that, in the lamprey, angiotensinogen is an active serpin, acting as 
an efficient heparin-activated inhibitor of thrombin [62,63].  It thus seems likely that 
angiotensinogen originated as a bifunctional protein with roles in both coagulation and blood 
pressure control, but that those functions diverged later in evolution, with the protease inhibitory 
activity having been lost in mammals. 
Overall Conclusions 
The solving of structural mechanisms often open new understandings in physiology and medicine. 
This is so with the finding from the structures of TBG and CBG of an unexpected allosteric 
regulation of hormone release at tissue level. The surprise with angiotensinogen was not so much in 
its having a novel hormone release mechanism unrelated to the serpin change of fold, as in the 
revelation of an unsuspected regulatory process at the very start of the pathway that controls blood 
pressure. The findings focused on the oxidation of a labile S-S bond and its contributory role in the 
pre-eclamptic hypertension of pregnancy [52]. What is still unexplored is the likelihood that other 
factors will be involved in modulating this initial stage in the angiotensin pathway, including 
nitrosylation [52,64] of the reduced sulphydryl bridge and the contribution of the (pro)renin 
receptor at both tissue and cellular level [65]. 
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Figure 1. Serpins and mechanisms of hormone release. a. Structures of the CBG-cortisol 
complex, showing the S-to-R change on cleavage of the reactive loop (yellow) in a side-view of 
CBG (PDB entry 2v95 [31], on left) and its insertion as the middle strand of the A-sheet (red) in a 
frontal view on right (PDB 2vdy [32]). Note that cortisol (space-filled) remains bound here to the 
cleaved-CBG on right. b. The earlier prediction by Stein et al 1991 [6], of reversible movements of 
the intact reactive loop in-and-out of the A-sheet (PDB 1ova, on left) are borne out in 
crystallographic detail in TBG on right (PDB 2ceo [30]). The imino-acid proline at P8 will impede 
full insertion of the loop. 
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Figure 2. Modulating binding affinity. Hormone pocket of TBG showing interactions with 
thyroxine [30].  a.  Small movements of the reactive loop with insertion of the P14 side chain 
(space-filling) will affect the plasticity and b. perturb the hydrogen bonding network stabilising the 
binding of thyroxine (sticks) within the pocket (PDB 2ceo). Circled in red is Ala191 the 
replacement of which abolishes the 'fever' boost in thyroxine release as in Fig 3. c. Stereo view 
showing how entry of the P14 side-chain (space-filling left) will sterically displace the underlying 
Tyr241 (right), as labelled in b. 
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Figure 3. Temperature responsive hormone release. Outline plots of the change in ratios of the 
binding affinities (Kd/Kd37) with temperature. a. With CBG [9] there will predictably be a near 
fivefold increase in free cortisol with a rise in body temperature to 42oC; b. with TBG [29] the 
increase in released thyroxine will be much less (full line), but its purposeful occurrence is 
evidenced (dashed line) by a mutation A191T (Fig 2b) in the Australian aboriginal that negates the 
boosted increase at temperatures above 37oC. A control is provided by an accompanying mutation 




Fig 4. Angiotensinogen and its complex with renin: a. Showing the amino-terminal 
superstructure anchored to the serpin framework of angiotensinogen (PDB 2wxw [52]) by two 
helices (dark grey) with the red arrow indicating the buried renin-cleavage site. b. Interaction with 
renin displaces a protruding CD peptide loop with the concerted movement of the angiotensin-
containing terminal into the active-site cleft of renin (PDB 2x0b [52]). 
 
